• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


H&T Presspart Low GWP Banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Business

Destiny Pharma and SporeGen get £800,000 grant for bacillus nasal spray for prevention of COVID-19

Destiny Pharma and SporeGen have agreed to co-develop a bacillus nasal spray as a prophylactic for prevention of COVID-19, with much of the project cost covered by an £800,000 grant from Innovate UK. Pan Group subsidiary Huro will develop and manufacture the formulation, and the companies say that they expect to begin clinical trials by early 2022. Preclinical … [Read more...] about Destiny Pharma and SporeGen get £800,000 grant for bacillus nasal spray for prevention of COVID-19

Diomics licenses Active Motif antibodies for COVID-19 nasal spray

US biotech Diomics Corporation has announced plans to develop a prophylactic nasal spray against COVID-19 using antibodies licensed from Active Motif. According to the company, the Dioguard nasal spray, currently in in vitro testing, uses nanobeads made from the company's Diomat biopolymer loaded with Active Motif's 414-1 human IgG monoclonal antibodies. Diomics … [Read more...] about Diomics licenses Active Motif antibodies for COVID-19 nasal spray

Savara discontinues development of Molgradex for NTM lung infections

Savara has discontinued development of Molgradex inhaled recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of nontuberculous mycobacterial (NTM) lung infection and will not restart the Phase 2a ENCORE study of Molgradex for NTM in cystic fibrosis patients, the company said. Development of Molgradex for the treatment of … [Read more...] about Savara discontinues development of Molgradex for NTM lung infections

Iconovo gets US patent covering the ICOres DPI

Swedish DPI company Iconovo said that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance regarding a patent covering Iconovo’s ICOres reservoir-based dry powder inhaler. The patent, titled "Dry Powder Inhaler," describes the design of the ICOres device. The company was granted a Japanese patent for ICOres in November 2019 and has … [Read more...] about Iconovo gets US patent covering the ICOres DPI

Bilim Pharmaceuticals launches Ventofor Combi Fix, delivered by the PowdAir Plus DPI

H&T Presspart and Hovione Technology have revealed their collaboration with Bilim Pharmaceuticals on a dry powder inhaler based on the PowdAir Plus device. H&T Presspart acquired global rights to the capsule based DPI device from Hovione Technology in 2017. According to the announcement, Bilim has launched the Ventofor Combi Fix budesonide/formoterol DPI for … [Read more...] about Bilim Pharmaceuticals launches Ventofor Combi Fix, delivered by the PowdAir Plus DPI

Virpax licenses Nanomerics’ MM2019 “molecular masking” nasal powder

Virpax Pharmaceuticals said that it has acquired exclusive North American rights to Nanomerics' MMS019 nasal powder, which it calls a "high density molecular masking spray" and which is intended to block viruses from taking hold in the respiratory tract. Virpax said that MMS019 is in preclinical development for the prevention of COVID-19, seasonal flu, and other … [Read more...] about Virpax licenses Nanomerics’ MM2019 “molecular masking” nasal powder

Medical Developments International buys back European Union rights to Penthrox inhaler from Mundipharma

Medical Developments International (MVP) has announced that it will buy back the European Union rights to its Penthrox methoxyflurane inhaler from Mundipharma for €3 million, plus a 5% royalty up to a maximum of €5 million. The companies plan a 6-month transition period beginning September 1, 2020. Penthrox is approved throughout Europe for the emergency treatment … [Read more...] about Medical Developments International buys back European Union rights to Penthrox inhaler from Mundipharma

Lannett gets rights to distribute Respirent’s generic Flovent Diskus in the US

According to Lannett, the company has signed an agreement with Chinese inhaled drug developer Respirent for exclusive rights to distribute Respirent's generic version of GSK's Flovent Diskus fluticasone propionate DPI, which is in early development. In October 2019, Lannett announced a US distribution deal with Respivent for that company's generic version of GSK's … [Read more...] about Lannett gets rights to distribute Respirent’s generic Flovent Diskus in the US

Union Therapeutics acquires option for TFF’s dry powder niclosamide

Danish pharma company Union Therapeutics has entered into an agreement with TFF Pharmaceuticals for an option to license TFF's dry powder niclosamide, the companies announced. The deal includes potential inhaled and oral formulations of niclosamide for the treatment of COVID-19 and is worth up to $210 million in milestone payments as well as royalties on any … [Read more...] about Union Therapeutics acquires option for TFF’s dry powder niclosamide

AstraZeneca increases production of FluMist Quadrivalent for 2020-2021 flu season

AstraZeneca has announced that the first doses of its FluMist Quadrivalent live intranasal flu vaccine for the 2020-2021 US influenza season have shipped. FluMist Quadrivalent is approved for use in children over the age of 2 and adults up to age 49. The company said that it has increased planned production of the vaccine by more than 25% in response to … [Read more...] about AstraZeneca increases production of FluMist Quadrivalent for 2020-2021 flu season

  • « Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 44
  • Page 45
  • Page 46
  • Page 47
  • Page 48
  • Interim pages omitted …
  • Page 152
  • Next Page »

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Intertek banner
    Bespak Leading the Green Transition banner
    © 2025 OINDPnews